Paris, France —16 September 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced the renewal of its Board of Directors.
The Board of Directors, which met on September 15th, 2022, decided to co-opt Mrs. Céline Fantin and Mr. Michel Picot as Directors to replace Mr. Philippe Goupit and Mr. Mathieu Simon, who are leaving, for the remaining term of their mandates (i.e. until the Annual General Meeting (AGM) to be called in 2024 to approve the financial statements for the year ending December 31, 2023). These appointments will be submitted for ratification at the next AGM of Lysogene in 2023. Mr. Michel Picot and Ms. Céline Fantin were also appointed respectively Chairman and member of the Audit Committee of the Board of Directors.
Céline Fantin will bring a new contribution to Lysogene with her expertise in audit and transformation programs in the pharmaceutical industry. Michel Picot will also provide to Lysogene his extensive experience in financing and strategy.
With the departure of Mr. David Schilansky, whose mandate expired at the General Meeting of June 24, 2022, the Board of Directors of Lysogene is now composed of 5 members, including 4 independent directors.
“We are very pleased to announce the appointment of a renewed Board of Directors at Lysogene, which reflects the new momentum in place within the Company. We wanted a tighter, action-oriented Board of Directors adapted to the current situation of Lysogene. Céline Fantin and Michel Picot have extensive experience in audit, financing, and strategy in the pharmaceutical sector, which will be valuable assets to enable Lysogene to face its current challenges and support its ambitions” said Karen Aiach, Founder, Chairman and Chief Executive Officer of Lysogene. “I would like to thank Philippe Goupit and Mathieu Simon for their contribution. The Board of Directors also thanks them for their participation in the work of the Board.”
Mme Céline Fantin said: “It is with great enthusiasm that I join the Board of Directors of Lysogene, whose innovative and ambitious project brings hope for improving the understanding of CNS diseases and the lives of young patients”.
M. Michel Picot said: “Lysogene’s mission and ambitions are an excellent motivation to join the Board of Directors of the Company. The quality of the Board I am joining, the management and the teams of Lysogene are fully in line with these ambitions and I am very honored to take part with them to the Lysogene adventure”.
Céline Fantin, graduated from EM Lyon and KEDGE, began her career at KPMG and spent 10 years auditing listed companies in the health and new technology sectors. She then joined bioMérieux Group (In Vitro Diagnostics) until 2017 as VP Internal Audit, Risks and Compliance, where she created these activities and carried out consulting missions in strategy, crisis management and transformation; activities that she also developed within Institut Mérieux, in the biotechnology sector. She is currently Chairman of Fantinnov SAS, a consulting firm specializing in strategy, transformation, and investment for executives of family-run companies and startups. Céline Fantin is also a director of the listed company ORAPI Group (professional hygiene), Chairman of the Audit Committee, and a member of the Risk Committee and the CSR Committee.
Michel Picot, an HEC graduate, also started his career in audit at Peat Marwick Mitchell & Co. before holding several executive positions in the industry, including Deputy CEO of Vivendi Telecom International until 2004. He is currently Chairman of Advest SAS, a strategy, management and investment consulting firm specializing in technology companies. Michel Picot is also a director of Eurobio Scientific (formerly Diaxonhit), a publicly traded biotechnology company specializing in diagnostics. He is a member of the Investment Committee and the Risk and Audit Committee of Invensys Pension Scheme and is also a member of the Advisory Boards of Bpifrance under the ETI Accelerator programs.
Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable delivery of gene therapies to the CNS to treat lysosomal diseases and other disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA is ongoing. An adaptive clinical trial in GM1 gangliosidosis is also ongoing. Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism. The Company also entered into an exclusive worldwide license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a novel gene therapy candidate for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations. www.lysogene.com.
Forward Looking Statement
This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2021 universal registration document, registered with the French Markets Authorities on April 19, 2022, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.
This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
Stéphane Durant des Aulnois
Chief Financial Officer
+ 33 1 41 43 03 99